In a surprising move, DuPont de Nemours announced a 51.2% reduction in its quarterly dividend, lowering the payout from $0.61 to $0.30 per share. The company cited the need to redirect cash toward debt reduction and growth initiatives, freeing up approximately $750 million annually. This decision comes despite DuPont’s solid free cash flow coverage—historically above 1.2 times the dividend—and follows back-to-back dividend increases over the past three years. Management emphasized that the new dividend level is sustainable under conservative cash flow forecasts and provides flexibility for future capital allocation.

Since early 2021, DuPont has completed the spinoff of its Electronics & Industrial segment and agreed to sell its Aramids business for $3.5 billion. These transactions are designed to concentrate resources on higher-margin, faster-growing specialties such as safety & construction, nutrition & biosciences, and mobility & materials. The Electronics spin-off alone created two independent companies with combined annual revenues of $10.7 billion, while the Aramids sale will reduce net debt by 15% once closed. Executives expect the streamlined portfolio to deliver mid-teens operating margins by fiscal 2025, up from 12.4% in the most recent quarter.

To complement the dividend adjustment, DuPont’s board authorized a new $2 billion share repurchase program, replacing the previous $500 million authorization that had less than $100 million remaining. Management highlighted that the current stock price trades near five-year trough levels, presenting an attractive opportunity to enhance long-term earnings per share. If fully executed over the next 18–24 months, the buyback could reduce share count by roughly 4%, potentially boosting EPS by 6–8% annually when combined with expected organic growth.

Over the past ten years, DuPont has pursued an aggressive portfolio reshaping strategy, spinning off or divesting more than $20 billion in legacy assets. Yet, the company’s total shareholder return has underperformed the S&P 500 by approximately 25 percentage points during this period. Critics point to execution delays on cost-synergy targets and margin pressures in cyclically exposed segments. In response, management has set new targets: a 10% annual revenue growth rate in core specialties and $1 billion of annual cost savings by fiscal 2024, aiming to reverse underperformance and deliver stronger returns.